Vatorsecurities.se använder sig av cookies för att ge dig som besökare en så bra upplevelse som möjligt.

News

Vator Securities rådger Xintela i 40,5 MSEK företrädesemission

12 June 2020

Vator Securities agerar som finansiell rådgivare i samband med transaktionen om SEK 40,5 miljoner.

Xintela är en innovatör i utvecklingen avregenerativa cellterapier och riktade cancerterapier baserade på denpatenterade markörteknologiplattformen XINMARK®.

Read More

Vator Securities advises LIDDS on 59,3 MSEK Directed and Rights Issue

11 June 2020

Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 59,3 million.

LIDDS is a Swedish-based pharmaceutical company which develops new innovative pharmaceutical products with its proprietary drug delivery technology NanoZolid®.

Read More

Vator Securities acted as Joint Bookrunner on 400 MSEK Immunovia directed share issue

4 June 2020

Vator Securities acted as Joint Bookrunner in connection with the transaction raising SEK 400 million.

Vator Securities was involved in more than two-third of the final allocations to local and international specialist investors, thereby strongly delivering upon the company’s goal to diversify its shareholder base.

Read More

Xbrane Biopharma: Pop up on your boards – “the third wave” of biosimilars is rather a tsunami

2 June 2020

Xbrane provides an exceptionally attractive exposure to the rapidly growing biosimilars market without the significant clinical and approval risk that is often present in biotech companies.

We maintain the Outperform rating and raise the target price to SEK 155 per share, corresponding to an equity value of SEK 3 billion non-diluted, derived from a project-based, risk-adjusted DCF valuation of the lead asset Xlucane with fairly conservative estimates; real-world data on biosimilars supports an even more bullish outlook.

Read More

Ascelia Pharma: A delay. Fundamentals for Mangoral remain unchanged

26 May 2020

Ascelia Pharma’s announcement of a three to six-month delay of the ongoing pivotal phase III SPARKLE study is not surprising given the circumstances with the ongoing covid-19 pandemic and its impact on clinical trials.

In our previous update, we estimated launch during 2022. The revised timeline has a marginal impact on our valuation as the DCF model is mainly impacted by the free cash flow in the final years of the forecast. Our risk-adjusted DCF valuation of the lead project Mangoral results in a value for Ascelia of SEK 52 per share, down from SEK 54 per share.

Read More

Vator Securities advises Xbrane Biopharma on 146 MSEK directed share issue

20 May 2020

Vator Securities acted as Global Coordinator and Sole Bookrunner in connection with the transaction raising SEK 146million.

The Directed Share Issue was directed to selected Swedish and international institutional investors, among others, TIN Fonder, Swedbank Robur Ny Teknik and current shareholders Swedbank Robur Medica, STADA Arzneimittel and Serendipity Group among others.

Read More

Vator Securities advises NextCell Pharma on 25 MSEK Rights Issue

15 May 2020

Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 25 million.

NextCell is a cell therapy company with its leading drug candidate, ProTrans™, a treatment for type 1 diabetes, in a clinical phase II.

Read More

Swiss Nordic Bio 2020

6 May 2020

Swiss Nordic Bio 2020 was held on 6 February in Zurich and was a collaboration between Vator Securities, the Embassy of Sweden, the Norwegian Embassy, Business Sweden and Business Finland.

Swiss Nordic Bio in Zurich is a high-level partnering and investor event where Swiss and Nordic biotech startups, pharmaceutical companies and investors meet.

Here you will find the film from the event.

Read More